Hypothesis

Adaptive, biomarker‑triggered senolytic therapy—where dasatinib + quercetin (D+Q) is administered only when a circulating senescence‑associated secretory phenotype (SASP) signature exceeds a predefined threshold—and concurrent low‑dose fisetin prophylaxis will prevent the epigenetic age acceleration and telomere shortening observed with fixed‑schedule D+Q, while achieving superior senescent cell clearance and functional outcomes.

Rationale

1. Baseline senescent cell burden predicts response – In osteoporotic postmenopausal women, only those in the highest tertile of p16⁺ T‑cell mRNA benefited from D+Q [1]. This indicates that a subset of individuals harbors a senescent cell load sufficient to drive pathology, whereas others may experience off‑target effects without clinical gain.

2. Fixed intermittent D+Q drives epigenetic aging – A 6‑month pilot showed increased epigenetic age acceleration (first‑generation clocks) and telomere attrition [2]. Dasatinib, a broad tyrosine‑kinase inhibitor, can induce transient DNA‑damage responses in proliferating stem/progenitor cells, leading to telomere erosion and epigenetic drift when administered irrespective of senescent load.

3. Fisetin mitigates adverse epigenetic effects – Adding fisetin to the D+Q regimen largely abrogated the epigenetic age acceleration and telomere loss [2]. Fisetin activates Nrf2‑dependent antioxidant pathways, upregulates telomerase reverse transcriptase (TERT) expression, and suppresses cGAS‑STING signaling triggered by cytosolic DNA, thereby protecting telomeres and limiting SASP‑mediated inflammatory signaling.

4. SASP components are actionable biomarkers – Circulating IL‑6, GDF15, MMP‑9, and CX3CL1 correlate with tissue senescent cell burden and predict responsiveness to senolytics in preclinical models. Real‑time monitoring of these analytes could identify the therapeutic window when senescent cells are actively secreting deleterious factors.

Mechanistic Insight

We propose that dasatinib‑induced DNA damage in non‑senescent, rapidly dividing cells (e.g., hematopoietic progenitors, intestinal crypt stem cells) is the primary driver of the observed telomere shortening and epigenetic age acceleration. This damage activates ATM/ATR‑p53 pathways, leading to heterochromatin loss and altered DNA‑methylation patterns. Fisetin, via Nrf2 activation, enhances expression of DNA‑repair enzymes (OGG1, XRCC1) and telomerase subunits, reducing persistent DNA lesions and telomere loss. Simultaneously, fisetin’s inhibition of cGAS‑STING diminishes IFN‑β production, curbing a feed‑forward loop that propagates epigenetic drift through STAT1‑mediated DNMT1 dysregulation.

When D+Q is given only during SASP spikes, the drug exposure is limited to periods when senescent cells are actively undergoing anti‑apoptotic dependence (elevated BCL‑2/BCL‑XL). This reduces the cumulative dasatinib burden on proliferating compartments, while fisetin continuously safeguards genome integrity and telomere maintenance. The result is a net decrease in senescent cell load without accelerating host aging biomarkers.

Testable Predictions

A randomized, double‑blind trial in adults aged 65‑80 with elevated baseline SASP (plasma IL‑6 > 2 pg/mL) will include three arms:

• Arm A (fixed): D+Q (100 mg + 1 g) on 2 consecutive days every 4 weeks for 6 months.
• Arm B (adaptive): D+Q administered only when plasma IL‑6, GDF15, and MMP‑9 collectively exceed the 75th percentile of baseline levels (measured weekly); fisetin 100 mg daily throughout.
• Arm C (fisetin only): Fisetin 100 mg daily, no D+Q.

Primary outcomes at 6 months:

• Change in GrimAge epigenetic acceleration (Δ years).
• Leukocyte telomere length (qPCR).
• Secondary: p16⁺ T‑cell mRNA burden, bone mineral density (lumbar spine), physical performance (Short Physical Performance Battery), and incidence of adverse events (thrombocytopenia, infections).

Predictions: Arm B will show no significant increase in GrimAge or telomere shortening versus baseline (Δ ≈ 0), while Arm A will replicate the previously observed acceleration (Δ > 1 year). Arm B will exhibit a greater reduction in p16⁺ T‑cell mRNA than Arm A due to timed dosing coinciding with peak senescent vulnerability, and will match or exceed Arm A in functional improvements. Arm C will improve functional endpoints modestly but will not reduce senescent cell burden as effectively as the senolytic arms.

Falsifiability

If Arm B demonstrates epigenetic age acceleration comparable to Arm A, or if adaptive SASP triggering fails to reduce senescent cell burden more than fixed dosing, the hypothesis is refuted. Conversely, a clear dissociation—SASP‑guided dosing preserving epigenetic and telomere metrics while enhancing senolysis—would support the notion that biomarker‑guided, intermittent senolysis combined with fisetin prophylaxis is essential for translating senolytic benefit into clinical practice without accelerating host aging.

References

[1] https://www.fighting.org/archives/2024/07/results-from-a-phase-2-trial-of-senolytic-therapy-dasatinib-and-quercetin-for-osteoporosis/ [2] https://www.aging-us.com/news-room/A-Longitudinal-Study-on-Dasatinib-Quercetin-and-Fisetin-Senolytic-Interventions [3] https://www.nad.com/news/fisetin-fights-frailty-new-study-shows-supplement-preserves-strength [4] https://www.aging-us.com/article/101202/text [5] https://journals.physiology.org/doi/full/10.1152/physiol.00003.2023 [6] https://doi.org/10.1038/s41593-019-0372-9 [7] https://doi.org/10.1038/s41467-020-18039-x }